Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04746924 · ClinicalTrials.gov registry record · Phase 3
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by BeiGene.
- Active
- Registry status
- Phase 3
- Development phase
- 662
- Enrollment target
- 20
- Study locations
NCT04746924: Active Phase 3 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by BeiGene.
NCT04746924 is a Phase 3 study of Non-Small Cell Lung Cancer and NSCLC that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 662 participants, roughly in line with the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04746924, a Phase 3 study of Non-Small Cell Lung Cancer and NSCLC, is active but no longer recruiting, sponsored by BeiGene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 662 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-L1 high, locally advanced/recurrent or untreated metastatic NSCLC.
Primary Outcome
OS is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method. OS was a pre-specified primary endpoint for Arms A and B only.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Placebo
- DRUG Tislelizumab
- DRUG Ociperlimab
Study Locations (20)
Queensland
- Pindara Private Hospital - Benowa
- The Prince Charles Hospital - Chermside
- Mater Cancer Care Centre - South Brisbane
- John Flynn Private Hospital - Tugun
New South Wales
- Concord Repatriation General Hospital - Concord
- Northern Cancer Institute - St Leonards
- Calvary Mater Newcastle - Waratah
California
- Providence Medical Foundation St Jude Heritage Healthcare - Fullerton
- Valkyrie Clinical Trials - Los Angeles
Florida
- Ocala Oncology Center Pl Dba Florida Cancer Affiliates Ocala - Ocala
- Advent Health Cancer Institute - Orlando
Other
- Centro Medical Austral - Buenos Aires
- Centro Para La Atencion Del Paciente Oncologico (Caipo) - San Miguel de Tucumán
Indiana
- Goshen Center For Cancer Care - Goshen
Kentucky
- Baptist Health Lexington - Lexington
Louisiana
- University Medical Center New Orleans West Jefferson Medical Center - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 662 participants |
| Start Date | 2021-06-08 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 3 |
What the registry record for NCT04746924 still lists
NCT04746924 is an interventional study that assigns participants to a tested intervention. The registered 662 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target.
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT04746924 names 20 study sites across 12 states, led by Queensland, New South Wales, California.
Frequently Asked Questions
What is clinical trial NCT04746924 about?
NCT04746924 is a clinical study titled "A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer". The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-L1 high, locally advanced/recurrent or untreated metastatic NSCLC.
What is the current status of trial NCT04746924?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 662 participants. The study started on 2021-06-08. Estimated completion is 2026-03-31.
What conditions does trial NCT04746924 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, NSCLC.
What interventions are being tested in trial NCT04746924?
The interventions under investigation include: Pembrolizumab (DRUG), Placebo (DRUG), Tislelizumab (DRUG), Ociperlimab (DRUG).
Who is sponsoring clinical trial NCT04746924?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04746924 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04746924's enrollment target sits among peer trials
662 48th of 454 higher than 407 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05254743 · 662 participants · Phase 3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- NCT07164443 · 663 participants · Phase 3
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- NCT06607341 · 664 participants · NA
Community Engagement Alliance Against Disparities
- NCT01185132 · 660 participants · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI